C-Cure Drug Analysis 2018: A Bone Marrow-Derived Stem Cell Therapy Aimed at Regenerating Cardiac Tissue Following Severe Damage Due to Myocardial Infarctions - ResearchAndMarkets.com

The "Drug analysis: C-Cure" drug pipelines has been added to ResearchAndMarkets.com's offering.

C-Cure is a bone marrow-derived stem cell therapy aimed at regenerating cardiac tissue following severe damage due to myocardial infarctions. C-Cure consists of a patient's own cells harvested from bone marrow, which are treated with Celyad's proprietary cell culture to form autologous heart muscle cells. These cells are then re-injected directly into the scar tissue of the patient's heart to repopulate the damaged areas and improve cardiac function.

Key Topics Covered:

List of Figures
Figure 1: C-Cure for chronic heart failure - SWOT analysis
Figure 2: Drug assessment summary of C-Cure for chronic heart failure
Figure 3: Drug assessment summary of C-Cure for chronic heart failure
Figure 4: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: C-Cure drug profile
Table 2: C-Cure's proposed Phase III trial design in chronic heart failure
Table 3: C-Cure completed late-phase data in chronic heart failure
Table 4: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country M, 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/p8rkdn/ccure_drug?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180216005306/en/